Athira Pharma logo

Athira Pharma Share Price Today

(NASDAQ: ATHA)

Athira Pharma share price is $0.4 & ₹34.79 as on 6 Mar 2025, 2.30 'hrs' IST

$0.4

0.03

(6.95%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Athira Pharma share price in Dollar and Rupees. Guide to invest in Athira Pharma stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Athira Pharma, along with analyst recommendations, forecasts, and comprehensive financials.

Athira Pharma share price movements

  • Today's Low: $0.37
    Today's High: $0.40

    Day's Volatility :7.5%

  • 52 Weeks Low: $0.36
    52 Weeks High: $4.21

    52 Weeks Volatility :91.34%

Athira Pharma (ATHA) Returns

PeriodAthira Pharma IncSector (Health Care)Index (Russel 2000)
3 Months
-40.16%
2.1%
0.0%
6 Months
-33.44%
-4.1%
0.0%
1 Year
-90.41%
2.2%
0.0%
3 Years
-95.93%
11.8%
-11.6%

Athira Pharma (ATHA) Key Statistics

in dollars & INR

Previous Close
$0.374
Open
$0.37
Today's High
$0.399
Today's Low
$0.37
Market Capitalization
$14.5M
Today's Volume
$28.4K
52 Week High
$4.21
52 Week Low
$0.3645
Revenue TTM
$0.0
EBITDA
$-110.9M
Earnings Per Share (EPS)
$-2.62
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-102.87%

How to invest in Athira Pharma Stock (ATHA) from India?

It is very easy for Indian residents to invest directly in Athira Pharma from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Athira Pharma stock in both Indian Rupees (INR) and US Dollars (USD). Search for Athira Pharma or ATHA on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Athira Pharma or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Athira Pharma shares which would translate to 2.174 fractional shares of Athira Pharma as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Athira Pharma, in just a few clicks!

Returns in Athira Pharma (ATHA) for Indian investors in Rupees

The Athira Pharma stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Athira Pharma investment value today

Current value as on today

₹15,219

Returns

₹84,781

(-84.78%)

Returns from Athira Pharma Stock

₹89,744 (-89.74%)

Dollar Returns

₹4,963 (+4.96%)

Indian investors sentiment towards Athira Pharma (ATHA)

-8%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Athira Pharma Stock from India on INDmoney has decreased by -8% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Athira Pharma

  • Perceptive Advisors LLC

    13.97%

  • BML Capital Management LLC

    7.18%

  • Vanguard Group Inc

    4.03%

  • Propel Bio Management LLC

    3.86%

  • Simplify Asset Management Inc.

    3.86%

  • TANG CAPITAL MANAGEMENT LLC

    1.55%

Analyst Recommendation on Athira Pharma

Buy

    66%Buy

    33%Hold

    0%Sell

Based on 12 Wall street analysts offering stock ratings for Athira Pharma(by analysts ranked 0 to 5 stars)

Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
4
4
4
Sell
0
0
0

Analyst Forecast on Athira Pharma Stock (ATHA)

What analysts predicted

Upside of 37.5%

Target:

$0.55

Current:

$0.40

Insights on Athira Pharma Stock (Ticker Symbol: ATHA)

  • Price Movement

    In the last 7 days, ATHA stock has moved down by -14.8%
  • ATHA vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 62.3% return, outperforming this stock by 152.9%
  • ATHA vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 47.7% return, outperforming this stock by 143.6%

Athira Pharma Technicals Summary

Sell

Neutral

Buy

Athira Pharma is currently in a neutral trading position according to technical analysis indicators.

Athira Pharma (ATHA) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Athira Pharma Inc logo
-27.44%
-33.44%
-90.41%
-95.93%
-97.81%
Regeneron Pharmaceuticals, Inc. logo
1.3%
-41.29%
-30.51%
9.2%
42.38%
Beone Medicines Ltd logo
15.19%
34.31%
61.3%
43.16%
68.1%
Vertex Pharmaceuticals Incorporated logo
3.37%
3.77%
18.06%
106.43%
121.36%
Alnylam Pharmaceuticals, Inc. logo
-11.52%
-3.4%
62.32%
49.04%
120.93%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Athira Pharma Inc logo
NA
NA
NA
0.0
-1.03
-0.52
NA
1.49
Regeneron Pharmaceuticals, Inc. logo
17.85
17.85
1.03
43.09
0.16
0.07
0.01
273.57
Beone Medicines Ltd logo
NA
NA
NA
1.43
-0.19
-0.06
NA
31.22
Vertex Pharmaceuticals Incorporated logo
32.84
NA
1.33
18.07
-0.03
0.13
NA
63.87
Alnylam Pharmaceuticals, Inc. logo
NA
NA
-0.49
0.57
-15.01
-0.03
NA
0.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Athira Pharma Inc logo
Buy
$14.5M
-97.81%
NA
0.0%
Regeneron Pharmaceuticals, Inc. logo
Buy
$74.9B
42.38%
17.85
31.07%
Beone Medicines Ltd logo
NA
$28.5B
68.1%
NA
-16.92%
Vertex Pharmaceuticals Incorporated logo
Buy
$124.1B
121.36%
32.84
-4.86%
Alnylam Pharmaceuticals, Inc. logo
Buy
$31.5B
120.93%
NA
-12.37%

About Athira Pharma

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
Organization
Athira Pharma
Employees
65
CEO
Dr. Mark J. Litton M.B.A., Ph.D.
Industry
Commercial Services

Management People of Athira Pharma

NameTitle
Dr. Mark J. Litton M.B.A., Ph.D.
President, CEO & Director
Mr. Robert Renninger
VP of Finance, Principal Financial Officer & Principal Accounting Officer
Dr. Kevin Church Ph.D.
Chief Scientific Officer
Ms. Julie Rathbun
Head of Investor Relations
Mr. Mark F. Worthington J.D.
General Counsel, Chief Compliance Officer & Corporate Secretary
Dr. Javier San Martin M.D.
Chief Medical Officer

Important FAQs about investing in ATHA Stock from India :

What is Athira Pharma share price today?

Athira Pharma share price today stands at $0.40, Open: $0.37 ; Previous Close: $0.37 ; High: $0.40 ; Low: $0.37 ; 52 Week High: $4.21 ; 52 Week Low: $0.36.

The stock opens at $0.37, after a previous close of $0.37. The stock reached a daily high of $0.40 and a low of $0.37, with a 52-week high of $4.21 and a 52-week low of $0.36.

Can Indians buy Athira Pharma shares?

Yes, Indians can invest in the Athira Pharma (ATHA) from India.

With INDmoney, you can buy Athira Pharma at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Athira Pharma at zero transaction cost.

How can I buy Athira Pharma shares from India?

It is very easy to buy Athira Pharma from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Athira Pharma (ATHA) be purchased?

Yes, you can buy fractional shares of Athira Pharma with INDmoney app.

What are the documents required to start investing in Athira Pharma stocks?

To start investing in Athira Pharma, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Athira Pharma Stock (ATHA)?

Today’s highest price of Athira Pharma (ATHA) is $0.40.

Today’s lowest price of Athira Pharma (ATHA) is $0.37.

What is today's market capitalisation of Athira Pharma?

Today's market capitalisation of Athira Pharma ATHA is 14.5M

What is the 52 Week High and Low Range of Athira Pharma Stock (ATHA)?

  • 52 Week High

    $4.21

  • 52 Week Low

    $0.36

What are the historical returns of Athira Pharma (ATHA)?

  • 1 Month Returns

    -27.44%

  • 3 Months Returns

    -33.44%

  • 1 Year Returns

    -90.41%

  • 5 Years Returns

    -97.81%

Who is the Chief Executive Officer (CEO) of Athira Pharma ?

Dr. Mark J. Litton M.B.A., Ph.D. is the current Chief Executive Officer (CEO) of Athira Pharma.